Semi-Annual Report — FY2026 H1
What TAIKO PHARMACEUTICAL CO.,LTD. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-13View the original on EDINET
How much it says
42Thin
What moved here
12named for the first time
Its own wording
18terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, revenue increased 9.3% year on year to ¥2,636 million. Overseas sales in the pharmaceutical business grew, while domestic sales remained sluggish. Operating income was ¥17 million, as higher selling, general and administrative expenses, including increased advertising expenses, changed the earnings structure.
Komori's summary of this document, not the document's own words.42Thin
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
45
Typical
52
Typical
62
Detailed
0
Almost nothing
15
Almost nothing
53
Typical
27
Almost nothing
7
Almost nothing
79
Very detailed
50
Typical
R&D spend80百万円Money spent making new things.
Cash left over-8億円Cash from the business, less what went into equipment.
Spent on equipment2億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.